Tibsovo Approved for Acute Myeloid Leukemia
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 20, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation
July 20, 2018 -- The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 20, 2018 Category: Drugs & Pharmacology Source Type: news

FDA OKs Targeted Agent Ivosidenib for Relapsed/Refractory AML FDA OKs Targeted Agent Ivosidenib for Relapsed/Refractory AML
The FDA has approved the first-in-class agent ivosidenib, which targets mutations in the IDH1 gene in acute myeloid leukemia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Cambridge's Agios wins FDA approval for second cancer drug
The FDA approved a cancer drug from Agios Pharmaceuticals Inc. on Friday after a Phase 1 clinical study found it aided a small group of patients suffering from a rare type of leukemia. Cambridge-based Agios (Nasdaq: AGIO) is developing treatments for several types of cancer, including acute myeloid meukemia, or AML. The rare blood and bone marrow disease worsens quickly and accounts for approximately one percent of cancer patients, according to the National Cancer Institute. Las t year, Agios won… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 20, 2018 Category: American Health Authors: Allison DeAngelis Source Type: news

Cambridge's Agios wins FDA approval for second cancer drug
The FDA approved a cancer drug from Agios Pharmaceuticals Inc. on Friday after a Phase 1 clinical study found it aided a small group of patients suffering from a rare type of leukemia. Cambridge-based Agios (Nasdaq: AGIO) is developing treatments for several types of cancer, including acute myeloid meukemia, or AML. The rare blood and bone marrow disease worsens quickly and accounts for approximately one percent of cancer patients, according to the National Cancer Institute. Las t year, Agios won… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 20, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

FDA OKs Targeted Agent for Acute Myeloid Leukemia
(MedPage Today) -- Approved therapies now available for IDH1- and IDH2-mutant disease (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 20, 2018 Category: American Health Source Type: news

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
FDA approves new drug for the treatment of adults with acute myeloid leukemia who have a specific genetic mutation and a companion diagnostic to detect specific mutations in the IDH1 gene in patients with AML (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 20, 2018 Category: American Health Source Type: news

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used to detect specific mutations in the IDH1 gene in patients with AML. (Source: World Pharma News)
Source: World Pharma News - July 20, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia
The protein tyrosine phosphatase PTPN11 is implicated in the pathogenesis of juvenile myelomonocytic leukemia (JMML), acute myeloid leukemia (AML), and other malignancies. Activating mutations in PTPN11 increase downstream proliferative signaling and cell survival. We investigated the signaling upstream of PTPN11 in JMML and AML cells and found that PTPN11 was activated by the nonreceptor tyrosine/serine/threonine kinase TNK2 and that PTPN11-mutant JMML and AML cells were sensitive to TNK2 inhibition. In cultured human cell–based assays, PTPN11 and TNK2 interacted directly, enabling TNK2 to phosphorylate PTPN11, whic...
Source: Signal Transduction Knowledge Environment - July 17, 2018 Category: Science Authors: Jenkins, C., Luty, S. B., Maxson, J. E., Eide, C. A., Abel, M. L., Togiai, C., Nemecek, E. R., Bottomly, D., McWeeney, S. K., Wilmot, B., Loriaux, M., Chang, B. H., Tyner, J. W. Tags: STKE Research Articles Source Type: news

Researchers map 'family trees' of acute myeloid leukemia
(Comprehensive Cancer Centre Gustave Roussy) For the first time, a team of international researchers have mapped the family trees of cancer cells in acute myeloid leukemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains what happens when a patient stops responding to the treatment, providing important clues about how to combine enasidenib with other anti-cancer drugs to produce longer-lasting remissions and to prevent relapse. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 16, 2018 Category: International Medicine & Public Health Source Type: news

Girl who missed years of school fighting cancer is voted prom queen
Charlotte Jenkins, 16, from Stockport in Greater Manchester battled against a rare form of acute myeloid leukaemia to be able to sit her GCSEs and go to her end of school prom. (Source: the Mail online | Health)
Source: the Mail online | Health - July 12, 2018 Category: Consumer Health News Source Type: news

New Findings Illuminate'Black Box of Leukemia'New Findings Illuminate'Black Box of Leukemia '
Researchers have identified genetic mutations that may occur years before acute myeloid leukemia actually develops, giving new clues as to how the disease begins.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Girl, 16, who missed three years of school fighting rare cancer is voted prom queen
Charlotte Jenkins, 16, from Stockport in Greater Manchester battled against a rare form of acute myeloid leukaemia to be able to sit her GCSEs and go to her end of school prom. (Source: the Mail online | Health)
Source: the Mail online | Health - July 12, 2018 Category: Consumer Health News Source Type: news

Roche announces submission of supplemental New Drug Application for Venclexta for people with previously untreated acute myeloid leukaemia who are ineligible for intensive chemotherapy
Roche today announced submission of a supplemental New Drug Application (sNDA) to the United States (U.S.) Food and Drug Administration (FDA) for Venclexta  (venetoclax), in combination with a hypomethylating agent or in combination with low dose cytarabine (LDAC), for treatment of people with previously untreated acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - July 12, 2018 Category: Pharmaceuticals Source Type: news

Genetic changes in blood may predict leukemia diagnosis
Studying genetic changes in blood, researchers have found a way to identify people at high risk of developing acute myeloid leukemia years before diagnosis. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 9, 2018 Category: Consumer Health News Source Type: news

Roots of leukemia reveal possibility of predicting people at risk
(Wellcome Trust Sanger Institute) Scientists have discovered that it is possible to identify people at high risk of developing acute myeloid leukemia (AML) years before diagnosis. Wellcome Sanger Institute researchers and collaborators found that patients with AML had genetic changes in their blood years before they suddenly developed the disease. The study published in Nature shows that further research could allow earlier detection and monitoring of people at risk of AML in the future. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2018 Category: Cancer & Oncology Source Type: news

Leukemia researchers discover way to predict healthy people at risk for developing AML
(University Health Network) An international team of leukemia scientists has discovered how to predict healthy individuals at risk of developing acute myeloid leukemia (AML), an aggressive and often deadly blood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2018 Category: Cancer & Oncology Source Type: news

FLT3 Inhibitor Quizartinib Improves Survival in AML FLT3 Inhibitor Quizartinib Improves Survival in AML
For the first time, a single agent has produced a survival benefit when compared to standard chemotherapy in a subgroup of patients with relapsed or refractory acute myeloid leukemia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Grants Priority Review for Pfizer ’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia
June 27, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted the company ’s New Drug Application and granted Priority Review designation for glasdegib, an investigational oral smoothened (SMO)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 27, 2018 Category: Drugs & Pharmacology Source Type: news

University of Colorado Cancer Centers Study Shows that without “Yoga...
Researchers successfully target leukemia stem cells while leaving healthy blood stem cells unharmed, paving the way for "sea change" in the way we treat acute myeloid leukemia.(PRWeb June 14, 2018)Read the full story at https://www.prweb.com/releases/2018/06/prweb15553957.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 14, 2018 Category: Pharmaceuticals Source Type: news

Roche presents new data across a range of blood cancers at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche presented new data from studies in several blood cancers, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML) at the 2018 ASCO Annual Meeting, 1-5 June, in Chicago, IL, United States. (Source: Roche Investor Update)
Source: Roche Investor Update - June 3, 2018 Category: Pharmaceuticals Source Type: news

Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions
(University of Texas M. D. Anderson Cancer Center) Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2018 Category: Cancer & Oncology Source Type: news

Penn-developed approach could limit toxicity of CAR T therapy in acute myeloid leukemia
(University of Pennsylvania School of Medicine) A new approach pioneered at the University of Pennsylvania's Abramson Cancer Center may provide a new path towards treating acute myeloid leukemia (AML) with CAR T cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2018 Category: Cancer & Oncology Source Type: news

U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
TOKYO, May 29, 2018 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has accepted, with Priority R... Biopharmaceuticals, Oncology, FDA Astellas Pharma, gilteritinib, Acute Myeloid Leukemia, FLT3 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 29, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
TOKYO, May 29, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. " Astellas " ) announced today that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the company's New Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 29, 2018 Category: Drugs & Pharmacology Source Type: news

A new Achilles' heel of blood cancer
(CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) Acute Myeloid Leukemia is an aggressive form of blood cancer. The diseased cells often carry mutated forms of a specific gene, which is known to function within large protein networks. Applying a combination of proteomic and genomic screens, researchers at CeMM and LBI-CR identified a protein crucial for the survival of the cancer cells. When this protein is lost, AML cells stop growing and accumulate DNA damage, which makes them more sensitive to anti-cancer drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 18, 2018 Category: Cancer & Oncology Source Type: news

Single surface protein boosts multiple oncogenic pathways in acute myeloid leukemia
(Rockefeller University Press) Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia (AML) plays a much wider role in the disease than previously thought. The study, which will be published May 17 in the Journal of Experimental Medicine, raises hopes that current efforts to target this signaling protein could be a successful strategy to treat AML and other blood cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 17, 2018 Category: Biology Source Type: news

Leukemia: Five easily overlooked signs you have the condition
LEUKEMIA, or blood cancer, symptoms are not always easily detected. The condition has several forms including acute myeloid leukaemia and chronic leukemia. You should look out for these five symptoms of the condition. (Source: Daily Express - Health)
Source: Daily Express - Health - May 10, 2018 Category: Consumer Health News Source Type: news

New CAR T case study shows promise in acute myeloid leukemia
(H. Lee Moffitt Cancer Center& Research Institute) According to a case study from trial published online ahead of print in the journal Haematologica, a patient has remained cancer free for nine months after being treated with CYAD-01, followed by a bone marrow transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 9, 2018 Category: Cancer & Oncology Source Type: news

Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Quizartinib is the first FLT3 inhibitor to demonstrate improved overall survival compared with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3-ITD mutations, a very aggressive form of the disease associated with poo... Biopharmaceuticals, Oncology Daiichi Sankyo Company, quizartinib, acute myeloid leukemia, FLT3 inhibitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 8, 2018 Category: Pharmaceuticals Source Type: news

Leukemia protective role of Y chromosome gene discovered
(Wellcome Trust Sanger Institute) Scientists have discovered the first leukemia protective gene that is specific to the male-only Y chromosome. Researchers at the Wellcome Sanger Institute and the University of Cambridge found that this Y-chromosome gene protects against the development of acute myeloid leukemia (AML) and other cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 7, 2018 Category: Biology Source Type: news

Novel pathway identified in development of acute myeloid leukemia with poor prognosis
(National University of Singapore, Yong Loo Lin School of Medicine) NUS researchers have discovered a new pathway by which a severe form of acute myeloid leukemia (AML) develops. The main player in the pathway, a protein called SHARP1, promotes leukemia development and maintenance, both on its own and through its actions on other genes. The discovery could lead to the development of novel SHARP1-specific treatments for this difficult-to-treat form of AML. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 24, 2018 Category: Biology Source Type: news

Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia
TOKYO, April 23, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) today announced that it submitted on March 23, 2018, a new drug application (NDA) for marketing approval of gilteritinib... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - April 23, 2018 Category: Drugs & Pharmacology Source Type: news

BIDMC-lead team develops new approach to study long non-coding RNAs
(Beth Israel Deaconess Medical Center) In a groundbreaking paper, investigators at the Cancer Research Institute Beth Israel Deaconess Medical Center developed a novel approach to identify and determine the functional role of lncRNAs relevant to chemotherapy resistance in Acute Myeloid Leukemia (AML). The new technique integrates information from publicly-available pharmacological data bases with leading-edge CRISPR technologies to screen for both coding and non-coding genes that influence response to treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 19, 2018 Category: Cancer & Oncology Source Type: news

Implications of Mutation Profiling in Myeloid Malignancies —PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies. (Source: CancerNetwork)
Source: CancerNetwork - April 16, 2018 Category: Cancer & Oncology Authors: Douglas Tremblay, MD John O. Mascarenhas, MD Kelsey Sokol, MD Raajit Rampal, MD Sheena Bhalla, MD Tags: Acute Myeloid Leukemia Hematologic Malignancies Myelodysplastic Syndromes Oncology Journal Review Article Source Type: news

Novel Drug Shows Promise Against Acute Myeloid Leukemia
April 11, 2018—(BRONX, NY)—In a study published online today in Science Translational Medicine,Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and advanced myelodysplastic syndrome (MDS), now underway atMontefiore Health System. (Source: Einstein News)
Source: Einstein News - April 11, 2018 Category: Universities & Medical Training Source Type: news

Novel drug shows promise against acute myeloid leukemia
(Albert Einstein College of Medicine) In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and advanced myelodysplastic syndrome (MDS), now underway at Montefiore Health System. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2018 Category: Cancer & Oncology Source Type: news

Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018
First Data Presentations for CAR T Programs, Including DLL3 in Small Cell Lung Cancer and FLT3 in Acute Myeloid Leukemia Pre-Clinical Data Evaluating Half-Life Extended Anti-BCMA BiTE® Presented for First-Time New Data Include two Studies Investigating Mcl-1 Inhibitor AMG 176 THOUSAND OAKS, Calif., April 9, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new pre-clinical data for several of its novel investigational oncology candidates will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018. Data spans Amgen's ...
Source: Amgen News Release - April 9, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Molecular Minimal Disease in Remission Predicts AML Relapse
WEDNESDAY, March 28, 2018 -- The detection of molecular minimal residual disease is associated with increased relapse rates in acute myeloid leukemia (AML), according to a study published in the March 29 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2018 Category: Pharmaceuticals Source Type: news

Childhood Acute Myeloid Leukemia (AML)
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 23, 2018 Category: General Medicine Source Type: news

Huntsman Cancer Institute joins national clinical trial targeting AML
(Huntsman Cancer Institute) Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia& Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 15, 2018 Category: International Medicine & Public Health Source Type: news

Targeting Cholesterol Pathway Shows Potential for AML Treatment
Researchers have discovered that AML cells require high levels of cholesterol for survival, so the cholesterol pathway could represent a potential therapeutic option for the disease. (Source: CancerNetwork)
Source: CancerNetwork - March 14, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Acute Myeloid Leukemia Hematologic Malignancies News Source Type: news

Study Demonstrates a Common Genetic Etiology for LCH, AML, and MF
Researchers examined more than 750 pedigrees of familial hematologic malignancies and found that the same genetic alteration may be responsible for Langerhans cell histiocytosis, acute myeloid leukemia, and primary idiopathic myelofibrosis. (Source: CancerNetwork)
Source: CancerNetwork - March 5, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Blood Disorders Hematologic Malignancies News Source Type: news

Girl, 10, was separated from her twin while she battled cancer
Amelia Wilson, from Billingham, County Durham, was first diagnosed with acute myeloid leukaemia in September 2015 and endured months of grueling chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - March 2, 2018 Category: Consumer Health News Source Type: news

Leukaemia symptoms - what is the aggressive blood cancer acute myeloid leukaemia?
LEUKAEMIA symptoms include pale skin and tiredness. These are the signs of the aggressive blood cancer that kills almost 5,000 people a year in the UK. (Source: Daily Express - Health)
Source: Daily Express - Health - February 27, 2018 Category: Consumer Health News Source Type: news

A mother Googled her toddler ’ s symptoms — and believes it may have saved the child ’ s life
It was a headline that captured her attention: “Boy, 13, died just A WEEK after being diagnosed with leukemia despite having NO symptoms beforehand.” Laura Handley, a mother of five, had been scrolling through Facebook when she was sucked into a story about a seemingly healthy 13-year-old boy who had died suddenly from an aggressive form of cancer called acute myeloid […]Related:Here’s what you should know about the flu season this yearFlu cases fall for the first time this awful influenza seasonCDC seeks new labs for bioterror pathogens to replace aging facility (Sour...
Source: Washington Post: To Your Health - February 24, 2018 Category: Consumer Health News Source Type: news

EU Says Yes to Mylotarg for AML, No to Adjuvant Sunitinib EU Says Yes to Mylotarg for AML, No to Adjuvant Sunitinib
Gemtuzumab ozogamicin (Mylotarg) has been recommended for approval in Europe for use in acute myeloid leukemia, but adjuvant sunitinib after kidney cancer surgery was turned down.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Acute Myeloid Leukemia Overview Video Acute Myeloid Leukemia Overview Video
This video discusses the pathophysiology and major clinical signs and symptoms of acute myeloid leukemia.Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 23, 2018 Category: Consumer Health News Tags: Med Students Commentary Source Type: news

New strategy to target transcription factor STAT5 to combat leukaemia
(University of Veterinary Medicine -- Vienna) Acute myeloid leukaemia is the most common type of acute cancer of the blood and bone marrow in adults. AML progresses quickly and only 26 percent of the patients survive longer than 5 years as resistance against established treatments arises. The most common molecular cause is FLT3 mutations, which result in hyper-activation of STAT5. A researcher consortium now reports on an early preclinical development to target STAT5 directly, which cooperates well with existing therapies. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 22, 2018 Category: Biology Source Type: news